On Friday, Arca Biopharma Inc (NASDAQ:ABIO)’s shares inclined 12.61% to $1.25.
ARCA biopharma, Inc. ( ABIO) declared the closing of the formerly declared private placement financing with a select group of institutional investors, counting lead investor Venrock, New Enterprise Associates (NEA), funds managed by Franklin Advisers, Inc., RA Capital Administration, Tekla Life Sciences Investors and other institutional investors. ARCA received net proceeds of about $34 million from the sale of about 42 million units at a price of $0.8805 per unit. Each unit comprises of one share of ARCA’s common stock and a warrant to purchase 0.40 shares of common stock with an exercise price of $0.8716. The warrants have a term of seven years and become exercisable 180-days after the closing date.
ARCA plans to use the anticipated proceeds from the private placement for working capital and clinical development of bucindolol, counting GENETIC-AF, the ongoing Phase 2B/3 trial for the prevention of atrial fibrillation. The Company anticipates that its current cash and cash equivalents and the net proceeds of this private placement will be sufficient to fund its operations, at the projected cost structure, through the end of 2017. However, changing circumstances may cause the Company to consume capital significantly faster or slower than presently anticipated.
ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacologically unique beta-blocker and mild vasodilator for the treatment of atrial fibrillation in patients with heart failure and left ventricular dysfunction. The company has a collaboration agreement with Medtronic, Inc. for the support of Gencaro’s Phase IIB/III clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
Envision Healthcare Holdings Inc (NYSE:EVHC)’s shares gained 1.01% to $38.98.
Envision Healthcare Holdings, Inc. (EVHC) plans to release its second quarter and year-to-date operating results for the three months and six months ended June 30, 2015, after the securities markets close on Thursday, July 30, 2015, with a conference call to follow at 5 p.m. Eastern Time.
Envision Healthcare Holdings, Inc. provides physician-led, outsourced medical services to consumers, hospitals, healthcare systems, health plans, and government entities in the United States. It offers a range of hospital-based physician staffing and related administration services, counting contract administration, staffing, recruiting, scheduling, operational improvement assessment, practice support, and practice improvement services for emergency departments, anesthesiology, hospitalist/inpatient care, radiology, tele-radiology, and surgery programs; and physician-led care administration solutions to patients outside the hospital.
At the end of Friday’s trade, Polycom Inc (NASDAQ:PLCM)‘s shares surged 0.81% to $11.26.
Demonstrating its commitment to driving highly productive partnership experiences, Polycom, Inc. (PLCM) declared at InfoComm 2015 three new solutions to its industry-leading Polycom® RealPresence® Platform. Polycom added advanced capabilities, extended benefits and cloud offers to the RealPresence Platform, making it recently most complete, affordable and accessible method of building and harnessing the workplace of the future.
Polycom, Inc. provides partnership solutions for voice, video, and content sharing. The company offers video, voice, and content-administration and content-sharing solutions, such as telepresence and conference room systems, home/work office solutions, applications for mobile devices, browser-based video collaboration, and cloud-delivered services, in addition to industry-specific solutions, counting specialized video carts and solutions for healthcare, education, and manufacturing.
Mueller Water Products, Inc. (NYSE:MWA), ended its Friday’s trading session with 1.03% gain, and closed at $8.82.
Mueller Water Products, Inc. (MWA) declared that it has filed a universal shelf registration statement on Form S-3 with the Securities and Exchange Commission (“SEC”). The shelf registration statement became effective upon filing. The new shelf registration statement replaces the Company’s expiring shelf registration statement and will permit the Company to offer and sell, from time to time, equity, debt or other types of securities described in the shelf registration statement, or any combination thereof, in one or more future public offerings.
The filing was made in order to continue to provide the Company with financial flexibility. The Company does not have any current plans to sell securities under the new registration statement. If and when the Company offers any securities under the new registration statement, the Company will prepare and make accessible a prospectus supplement that comprises the specific terms of the securities being offered, the use of proceeds and other terms of the offering.
Mueller Water Products, Inc. manufactures and markets products and services for the use in transmission, distribution, and measurement of water in the United States, Canada, and internationally. The company operates in two segments, Mueller Co. and Anvil. The Mueller Co. segment offers valves for water and gas systems, counting iron gate, butterfly, tapping, check, plug, and ball valves; dry-barrel and wet-barrel fire hydrants; pipe repair products, such as clamps and couplings used to repair leaks; small valves, meter bars, and line stopper fittings for use in gas systems; machines and tools for tapping, drilling, extracting, installing, and stopping-off; and municipal castings comprising manhole covers and street drain grates. It also provides residential and commercial metering products and systems; and leak detection and pipe condition assessment products and services. T
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
